Inhibrx Biosciences, Inc.
INBX
$14.00
$0.000.00%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | ||
|---|---|---|---|---|---|
| Revenue | -93.88% | -- | 233.33% | -100.00% | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -93.88% | -- | 233.33% | -100.00% | |
| Cost of Revenue | -59.35% | 2.20% | 98.30% | 70.79% | |
| Gross Profit | 58.65% | -2.52% | -98.18% | -70.87% | |
| SG&A Expenses | -759.31% | 0.19% | 1,185.50% | 55.92% | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | -120.06% | 1.85% | 289.18% | 68.62% | |
| Operating Income | 120.55% | -2.12% | -289.22% | -68.68% | |
| Income Before Tax | 48.87% | 15.30% | 4,049.27% | -60.91% | |
| Income Tax Expenses | 100.00% | -- | -60.00% | -- | |
| Earnings from Continuing Operations | 48.86% | 15.30% | 4,048.85% | -60.91% | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | 48.86% | 15.30% | 4,048.85% | -60.91% | |
| EBIT | 120.55% | -2.12% | -289.22% | -68.68% | |
| EBITDA | 121.40% | -1.13% | -290.84% | -69.00% | |
| EPS Basic | 55.27% | 35.45% | 3,047.28% | -28.51% | |
| Normalized Basic EPS | 118.88% | 35.45% | -159.36% | -28.51% | |
| EPS Diluted | 55.25% | 35.36% | 3,009.82% | -28.51% | |
| Normalized Diluted EPS | 118.88% | 35.45% | -156.07% | -28.51% | |
| Average Basic Shares Outstanding | 14.33% | 31.22% | 33.98% | 25.21% | |
| Average Diluted Shares Outstanding | 14.33% | 31.22% | 35.71% | 25.21% | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |
